Agyare EK, Jaruszewski KM, Curran GL, Rosenberg JT, Grant SC, Lowe VJ, et al
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)
Maddams J, Utley M and Mller H
For the full conversion chart and detailed dose conversion protocols , those resources provide the exact numbers for each dose level
Early research suggests it may slow age-related metabolic decline
From a regulatory standpoint, microdosing is off label and not endorsed by manufacturers or health authorities